drugset

drugset / Trial / NCT02412228

Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma

NCT02412228 ↗

Phase 2 Completed 12 enrolled John L. Reagan Memorial Hospital of Rhode Island · collab Rhode Island Hospital · collab The Miriam Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this proposal is to develop a more effective and better tolerated regimen. Ixazomib appears to have greater activity than bortezomib with less peripheral neuropathy.

Timeline

Start: 2015-08
Primary completion: 2019-03-29
Completion: 2023-11-09

Publications

Pelcovits A, Barth P, Reagan JL, Olszewski AJ, Rosati V, Wood R, Sturtevant A, Winer ES. Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study. Oncologist. 2023 May 8;28(5):462-e303. doi: 10.1093/oncolo/oyad017.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	50 mg	Oral
Subject	Dexamethasone	Small molecule	20 mg	Oral
Subject	Ixazomib	Unknown	4 mg	Oral

Indications